DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "EpiCast Report: Ulcerative Colitis - Epidemiology Forecast to 2025" drug pipelines to their offering.
In the 7MM, the epidemiologists forecast that the diagnosed incident cases of UC will increase from 86,509 cases in 2015 to 95,864 cases in 2025, at an annual growth rate (AGR) of 1.08%. The US will have the highest number of diagnosed incident cases of UC over the forecast period, while Spain will have the lowest.
In the 7MM, the epidemiologists forecast that the diagnosed prevalent cases of UC will increase from 1,628,113 cases in 2015 to 1,711,603 cases in 2025, at an AGR of 0.51%. The US will have the highest number of diagnosed prevalent cases of UC over the forecast period, while Spain will have the lowest.
To forecast the diagnosed incident and diagnosed prevalent cases of UC in the 7MM, the epidemiologists used country-specific studies and peer-reviewed journals that provided age- and sex-specific diagnosed incidence and/or diagnosed prevalence of UC in the respective markets. The forecast methodology was consistent across the 7MM to allow for a meaningful comparison of the forecast incident and prevalent cases of UC across these markets.
Key Topics Covered:
1 Tables & Figures
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global Trends
2.4 Forecast Methodology
2.5 Epidemiological Forecast for UC (2015-2025)
2.5.1 Diagnosed Incident Cases of UC
2.5.2 Diagnosed Prevalent Cases of UC
2.5.3 Undiagnosed Prevalent Cases of UC
2.5.4 Total Prevalent Cases of UC
2.5.5 Diagnosed Incident Cases of IC
2.5.6 Diagnosed Prevalent Cases of IC
2.6.1 Epidemiological Forecast Insight
2.6.2 Limitations of the Analysis
2.6.3 Strengths of the Analysis
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/h2rmh6/epicast_report